|
41 Companies |
|
29 Products |
|
29 Products |
|
22 Mechanisms of Action |
|
2 Trials |
|
854 News |
|
| «12...567891011121314151617» |
- | New P1 trial: Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions (clinicaltrials.gov) - May 2, 2012
P1, N=28, Completed, Sponsor: Roxane Laboratories
- || New P3 trial: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC (clinicaltrials.gov) - Apr 29, 2012
P3, N=500, Recruiting, Sponsor: Institute of Tropical Medicine, Belgium
- | artemether/lumefantrine / Generic mfg.
Trial completion: Trial of Malaria Seasonal IPTc Combined With Community Case Management (clinicaltrials.gov) - Apr 24, 2012
P3, N=4554, Completed, Sponsor: Cheikh Anta Diop University, Senegal
Recruiting --> Completed
- New P1/2 trial: ChallengeIII: Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge (clinicaltrials.gov) - Apr 22, 2012
P1/2, N=16, Completed, Sponsor: Socrates Herrera Valencia
- |||| artemether/lumefantrine / Generic mfg.
Trial completion: A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem (clinicaltrials.gov) - Apr 22, 2012
P4, N=14075, Completed, Sponsor: Novartis
Recruiting --> Completed Recruiting --> Completed
- methotrexate / Generic mfg.
Trial completion: Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers (clinicaltrials.gov) - Apr 19, 2012
P1, N=25, Completed, Sponsor: KEMRI-Wellcome Trust Collaborative Research Program
Recruiting --> Completed Not yet recruiting --> Completed
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Enrollment open, Head-to-Head: Efficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in Ghana (clinicaltrials.gov) - Apr 18, 2012
P3, N=904, Recruiting, Sponsor: Kwame Nkrumah University of Science and Technology
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition (clinicaltrials.gov) - Apr 17, 2012
P=N/A, N=860, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Enrollment change: Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children (clinicaltrials.gov) - Apr 16, 2012
P4, N=7680, Completed, Sponsor: University of California, Davis
Not yet recruiting --> Completed N=6300 --> 7680
- Trial completion: Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children (clinicaltrials.gov) - Apr 16, 2012
P4, N=7680, Completed, Sponsor: University of California, Davis
N=6300 --> 7680 Recruiting --> Completed
- | trimethoprim/sulfamethoxazole / Generic mfg., sulfadoxine/pyrimethamine / Generic mfg.
Enrollment change: PROMOTE-Chemop: Chemopreventive Therapy for Malaria in Ugandan Children (clinicaltrials.gov) - Apr 15, 2012
P3, N=600, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed N=800 --> 600
- | trimethoprim/sulfamethoxazole / Generic mfg., sulfadoxine/pyrimethamine / Generic mfg.
Enrollment closed: PROMOTE-Chemop: Chemopreventive Therapy for Malaria in Ugandan Children (clinicaltrials.gov) - Apr 15, 2012
P3, N=600, Active, not recruiting, Sponsor: University of California, San Francisco
N=800 --> 600 Recruiting --> Active, not recruiting
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Trial withdrawal: Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection (clinicaltrials.gov) - Apr 11, 2012
P2/3, N=0, Withdrawn, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Trial termination, Combination therapy: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV) (clinicaltrials.gov) - Apr 11, 2012
P4, N=16, Terminated, Sponsor: Centers for Disease Control and Prevention
Not yet recruiting --> Withdrawn Not yet recruiting --> Terminated; Extremely slow enrollment
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Trial termination, Combination therapy: PAACT-PF: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil (clinicaltrials.gov) - Apr 11, 2012
P4, N=6, Terminated, Sponsor: Centers for Disease Control and Prevention
Not yet recruiting --> Terminated; Extremely slow enrollment Recruiting --> Terminated; Extremely slow enrollment
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Trial initiation date, Combination therapy: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV) (clinicaltrials.gov) - Apr 11, 2012
P4, N=16, Terminated, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Terminated; Extremely slow enrollment Initiation date: Sep 2010 --> Feb 2011
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Trial initiation date, Combination therapy: PAACT-PF: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil (clinicaltrials.gov) - Apr 11, 2012
P4, N=6, Terminated, Sponsor: Centers for Disease Control and Prevention
Initiation date: Sep 2010 --> Feb 2011 Initiation date: Jul 2010 --> Nov 2010
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Enrollment change, Combination therapy: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV) (clinicaltrials.gov) - Apr 11, 2012
P4, N=16, Terminated, Sponsor: Centers for Disease Control and Prevention
Initiation date: Jul 2010 --> Nov 2010 N=720 --> 16
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Enrollment change, Combination therapy: PAACT-PF: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil (clinicaltrials.gov) - Apr 11, 2012
P4, N=6, Terminated, Sponsor: Centers for Disease Control and Prevention
N=720 --> 16 N=274 --> 6
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Enrollment change: Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection (clinicaltrials.gov) - Apr 11, 2012
P2/3, N=0, Withdrawn, Sponsor: Centers for Disease Control and Prevention
N=274 --> 6 N=56 --> 0
- chloroquine phosphate / Generic mfg.
Trial completion: ZonMw1: Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis (clinicaltrials.gov) - Mar 29, 2012
P=N/A, N=30, Completed, Sponsor: Radboud University
N=56 --> 0 Active, not recruiting --> Completed
- ||| New P1 trial: Tafenoquine Thorough QTc Study in Healthy Subjects (clinicaltrials.gov) - Mar 28, 2012
P1, N=260, Completed, Sponsor: GlaxoSmithKline
- primaquine / Generic mfg.
Enrollment change: Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra (clinicaltrials.gov) - Mar 21, 2012
P4, N=77, Completed, Sponsor: Indonesia University
Active, not recruiting --> Completed N=6484 --> 77
- primaquine / Generic mfg.
Trial completion: Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra (clinicaltrials.gov) - Mar 21, 2012
P4, N=77, Completed, Sponsor: Indonesia University
N=6484 --> 77 Recruiting --> Completed
- FMP010 / GSK, Walter Reed Army Institute of Research
Enrollment change: A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya (clinicaltrials.gov) - Mar 15, 2012
P1, N=56, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Completed N=26 --> 56
- | chloroquine phosphate / Generic mfg.
Enrollment open: Chloroquine for Malaria in Pregnancy (clinicaltrials.gov) - Mar 14, 2012
P3, N=900, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=26 --> 56 Not yet recruiting --> Recruiting
- Trial completion: Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=6456, Completed, Sponsor: Mbarara University of Science and Technology
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Mosquirix (RTS,S) / GSK
New P1/2 trial: Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S (clinicaltrials.gov) - Mar 13, 2012
P1/2, N=72, Completed, Sponsor: U.S. Army Office of the Surgeon General
- | New P4 trial: Pop PK Chagast: Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease (clinicaltrials.gov) - Mar 7, 2012
P4, N=80, Active, not recruiting, Sponsor: Drugs for Neglected Diseases
- PfSPZ Vaccine / Sanaria
New P1 trial: Sanaria (clinicaltrials.gov) - Mar 5, 2012
P1, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | New P1 trial: Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults (clinicaltrials.gov) - Feb 27, 2012
P1, N=30, Completed, Sponsor: Sanaria Inc.
- ||||| New P4 trial: Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease (clinicaltrials.gov) - Feb 23, 2012
P4, N=102, Recruiting, Sponsor: Medtronic Cardiac Rhythm Disease Management
- | Trial completion: Experimental Human Malaria Infection by PfSPZ (clinicaltrials.gov) - Feb 22, 2012
P1, N=18, Completed, Sponsor: Sanaria Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso (clinicaltrials.gov) - Feb 22, 2012
P1, N=48, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- carvedilol / Generic mfg.
New P4 trial: A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy (clinicaltrials.gov) - Feb 20, 2012
P4, N=42, Completed, Sponsor: Federal University of Minas Gerais
- artemether/lumefantrine / Generic mfg.
Trial completion, Combination therapy: Treatment of Non-falciparum Malaria (clinicaltrials.gov) - Feb 15, 2012
P=N/A, N=40, Completed, Sponsor: Albert Schweitzer Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- |||||| Enrollment open: Babesia Testing in Blood Donors (clinicaltrials.gov) - Feb 13, 2012
P3, N=26000, Recruiting, Sponsor: Imugen
Recruiting --> Completed Withheld --> Recruiting
- | Enrollment change: Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen (clinicaltrials.gov) - Feb 12, 2012
P2, N=50, Completed, Sponsor: Nielsen BioSciences, Inc.
Withheld --> Recruiting N=36 --> 50
- acoziborole (SCYX-7158) / SCYNEXIS
New P1 trial: Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 (clinicaltrials.gov) - Feb 12, 2012
P1, N=120, Recruiting, Sponsor: Drugs for Neglected Diseases
- Fexinidazole Winthrop (fexinidazole) / Sanofi
Trial termination: Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food (clinicaltrials.gov) - Feb 9, 2012
P1, N=30, Terminated, Sponsor: Drugs for Neglected Diseases
N=36 --> 50 Recruiting --> Terminated; poor tolerability at highest dose
- Enrollment change: Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark) (clinicaltrials.gov) - Feb 8, 2012
P1, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Terminated; poor tolerability at highest dose N=100 --> 30
- ||| Enrollment closed: MSP3-POC: Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa (clinicaltrials.gov) - Feb 5, 2012
P2b, N=800, Active, not recruiting, Sponsor: Vac4All
N=100 --> 30 Recruiting --> Active, not recruiting
- Trial termination: Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria (clinicaltrials.gov) - Feb 1, 2012
P2, N=20, Terminated, Sponsor: Sanofi
Recruiting --> Active, not recruiting Suspended --> Terminated; Data Monitoring Committee recommendation
- Enrollment change: Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria (clinicaltrials.gov) - Feb 1, 2012
P2, N=20, Terminated, Sponsor: Sanofi
Suspended --> Terminated; Data Monitoring Committee recommendation N=180 --> 20
- Trial initiation date: PIMAL: Prenatal Iron and Malaria Study (clinicaltrials.gov) - Jan 31, 2012
P4, N=470, Completed, Sponsor: London School of Hygiene and Tropical Medicine
N=180 --> 20 Initiation date: Apr 2011 --> Oct 2011
- |||||||||| New P3 trial: Babesia Testing in Blood Donors (clinicaltrials.gov) - Jan 30, 2012
P3, N=26000, Recruiting, Sponsor: Imugen
- | cipargamin (KAE609) / Novartis
New P2 trial: Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection (clinicaltrials.gov) - Jan 30, 2012
P2, N=27, Completed, Sponsor: Novartis Pharmaceuticals
- | Trial initiation date: Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis (clinicaltrials.gov) - Jan 26, 2012
P2, N=40, Completed, Sponsor: University of Alabama at Birmingham
Initiation date: Apr 2011 --> Oct 2011 Initiation date: Jul 2011 --> Dec 2011
- | artemether/lumefantrine / Generic mfg.
Enrollment change, Combination therapy: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children (clinicaltrials.gov) - Jan 26, 2012
P3, N=323, Completed, Sponsor: Centers for Disease Control and Prevention
Initiation date: Jul 2011 --> Dec 2011 N=842 --> 323
- | artemether/lumefantrine / Generic mfg.
Trial completion, Combination therapy: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children (clinicaltrials.gov) - Jan 26, 2012
P3, N=323, Completed, Sponsor: Centers for Disease Control and Prevention
N=842 --> 323 Recruiting --> Completed